TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04824898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Statins are first known as drugs that decrease the cholesterol level by inhibiting hydroxy-methyl-glutaryl co-enzyme-A reductase as they improve the lipid profile and help in the treatment of many cardiac diseases and has a role in osteoblasts diffrentiation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: injectable plasma rich fibrin
Description: I- PRF is obtained by taking a blood sample from patients and then is centrifuged for three minutes at 3300 rpm, the I-PRF first will be in the form of liquid and then coagulate after few minutes from the injection
Study: NCT05502237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered intravenously
Study: NCT06082167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanzalintinib
Description: Specified doses on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zanzalintinib-matched Placebo
Description: Specified doses on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Specified doses on specified days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: Specified doses on specified days
Study: NCT05440708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-101
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-101
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-101
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenous (IV) infusion
Study: NCT05438212

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brain Surgery
Description: Undergo surgery per standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain Surgery
Description: Undergo surgery per standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: Undergo stereotactic radiosurgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo stereotactic radiosurgery
Study: NCT05613036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]-BI 907828 mixed with BI 907828 (formulation 1)
Description: \[¹⁴C\]-BI 907828 mixed with BI 907828 (formulation 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]-BI 907828 mixed with BI 907828 (formulation 2)
Description: \[¹⁴C\]-BI 907828 mixed with BI 907828 (formulation 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 907828
Description: BI 907828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 907828
Description: BI 907828
Study: NCT06264921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKT3447
Description: Oral CDK2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKT3447
Description: Oral CDK2 inhibitor
Study: NCT05399537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prismocitrate 18
Description: Prismocitrate 18 solution (investigational drug) will be used in pre-dilution mode only; the rate of administration depends on the targeted citrate dose and the prescribed flow rate. The pre-filter infusion rate of Prismocitrate 18 solution will be indexed to the blood flow rate (BFR) to achieve a target blood citrate concentration of 3 mmol/L of blood. The flow rate for the anticoagulation of the extracorporeal circuit will be titrated to achieve a post-filter concentration of iCa of 0.25 to 0.35 mmol/L.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrisMax System Version 3.x with calcium line accessory
Description: The RCA software on PrisMax System Version 3.x with calcium line accessory (investigational device) will be enabled to carefully guide the health practitioner for citrate dosing and calcium compensation.
Study: NCT05269667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab 120 mg
Description: Satralizumab 120 mg will be administered as monotherapy (SC) in the abdominal or femoral region at Weeks 0, 2 (±3 days), 4 (±3 days), and then every 4 weeks (±3 days) till the last administration at Week 92 followed by a clinical evaluation at Week 96. The first dose at Weeks 0 (baseline visit) will be administered at the study site by the designated site staff during the scheduled study visit. The next dose at Week 2 will be self-administered by the patient under the supervision of a designated study staff at the study site. All the subsequent doses will be self-administered by the patient following training from a healthcare provider (for patients who are not able to administer satralizumab SC by themselves, support by a caregiver/nurse is advised).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab 120 mg
Description: Satralizumab 120 mg will be administered as monotherapy (SC) in the abdominal or femoral region at Weeks 0, 2 (±3 days), 4 (±3 days), and then every 4 weeks (±3 days) till the last administration at Week 92 followed by a clinical evaluation at Week 96. The first dose at Weeks 0 (baseline visit) will be administered at the study site by the designated site staff during the scheduled study visit. The next dose at Week 2 will be self-administered by the patient under the supervision of a designated study staff at the study site. All the subsequent doses will be self-administered by the patient following training from a healthcare provider (for patients who are not able to administer satralizumab SC by themselves, support by a caregiver/nurse is advised).
Study: NCT05495269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS-101 ophthalmic solution, 2.0 %
Description: ophthalmic solution in a single use dropper vial
Study: NCT05302375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPath*D
Description: Online pathway from screening to treatment for depression in cancer patients.
Study: NCT04454489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (immunotherapy)
Description: Pembrolizumab 200 mg will be given every 3 weeks to tumor progression or treatment tolerance.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Quad-shot palliative radiotherapy
Description: * Each cycle of quad-shot radiotherapy will be comprised of 14.8 Gy in 4 fractions (3.7 Gy per fraction) delivered twice daily (at least 6 hours apart) over two consecutive days.~* All patients will receive 1 cycle of quad-shot radiotherapy between ICI cycles 2-3.~* Subsequent cycles may occur between immunotherapy cycles 6-7 and 11-12, if more than 1 cycle can be safely delivered and the patient has experienced less than a partial response at protocol-specified tumor assessments (after C5 and C10). The eligibility for subsequent cycles will be at the discretion of the treating radiation oncologist.~Therefore, the total prescription dose will be:~* 14.8 Gy in 4 fractions for those that complete 1 cycle (all patients will receive 1 cycle)~* 19.6 Gy in 8 fractions for those that complete 2 cycles~* 44.4 Gy in 12 fractions for those that complete 3 cycles
Study: NCT05745246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-health training program
Description: 1. Health letters, 44 issues of 90SecondFire Cancer health letters delivered twice a week during six months to firefighters by text or email~2. A problem-solving asynchronous chat room which encourages mutual support and exchange of ideas via a closed asynchronous bulletin board for peer-to-peer support~3. A brief 45-minute pre-recorded online course; it is intended as a summative exercise rather than providing new information.
Study: NCT06500455

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated Stereotactic Radiation Therapy
Description: Undergo FSRS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS
Study: NCT05524922

Intervention type: OTHER
Intervention: Data collection
Description: Neuropsychological assessment, brain MRI, electroencephalogram and biomarker datas will be collected
Study: NCT04969094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Description: Participants will receive NMES to the hip abductors while performing strength training 3 times per week for 3-months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multi-Modality Balance Intervention (MMBI)
Description: Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 3-months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-Modality Balance Intervention (MMBI)
Description: Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 3-months
Study: NCT06311682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab + TCS
Description: The trial medication will be given under the skin (SC). Dose and dosing frequency for each subject will depend on the subject's body weight. Subjects who will receive treatment every two weeks will receive a loading dose corresponding to a double dose at baseline. Subjects who will receive treatment every 4 weeks will receive a staggered loading dose at baseline and Week 2. After the loading dose, they will continue to receive treatment every 4 weeks. The dose and dosing frequency will be adjusted according to the subject's body weight at weeks 16, 32, 52, 64, 88, 112, 136, 160, and 184.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab + TCS
Description: The trial medication will be given under the skin (SC). Dose and dosing frequency for each subject will depend on the subject's body weight. Subjects who will receive treatment every two weeks will receive a loading dose corresponding to a double dose at baseline. Subjects who will receive treatment every 4 weeks will receive a staggered loading dose at baseline and Week 2. After the loading dose, they will continue to receive treatment every 4 weeks. The dose and dosing frequency will be adjusted according to the subject's body weight at weeks 16, 32, 52, 64, 88, 112, 136, 160, and 184.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo + TCS
Description: The trial medication will be given under the skin (SC). Dose and dosing frequency for each subject will depend on the subject's body weight. Subjects who will receive treatment every two weeks will receive a loading dose corresponding to a double dose at baseline. Subjects who will receive treatment every 4 weeks will receive a staggered loading dose at baseline and Week 2. After the loading dose, they will continue to receive treatment every 4 weeks. The dose and dosing frequency will be adjusted according to the subject's body weight at weeks 16, 32, 52, 64, 88, 112, 136, 160, and 184.
Study: NCT06033833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Injection Solution: by subcutaneous injection (SCI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injection Solution: by subcutaneous injection (SCI)
Study: NCT05058508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Just Move Exercise
Description: Subjects complete Just Move Exercises Five Times Per Week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care Exercise
Description: Subjects exercise/move as tolerated
Study: NCT03962062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin
Description: 2 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin
Description: 2 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin
Description: 2 mg tablets
Study: NCT05034328

Intervention type: DEVICE
Intervention: Healsea® Children
Description: Children will be administered Healsea Children , one puff (1-2 sec) in each nostril twice a day for 10 days on top of conventional therapies, as needed

Intervention type: OTHER
Intervention: Conventional therapies for common cold
Description: Children will receive conventional therapies for common cold, nasal irrigation excluded (antipyretics, mucolytics, decongestants, antitussives, systemic and topical corticosteroids, antibiotics)

Intervention type: OTHER
Intervention: Conventional therapies for common cold
Description: Children will receive conventional therapies for common cold, nasal irrigation excluded (antipyretics, mucolytics, decongestants, antitussives, systemic and topical corticosteroids, antibiotics)
Study: NCT06255028

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTY-101
Description: CNTY-101 cells for intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTY-101
Description: CNTY-101 cells for intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTY-101
Description: CNTY-101 cells for intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTY-101
Description: CNTY-101 cells for intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepleting Chemotherapy
Description: LDC as prespecified in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepleting Chemotherapy
Description: LDC as prespecified in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepleting Chemotherapy
Description: LDC as prespecified in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepleting Chemotherapy
Description: LDC as prespecified in the protocol.
Study: NCT04906902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Tablet taken by mouth twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Tablet taken by mouth twice daily
Study: NCT04657835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cardiac Magnetic Resonance Imaging (MRI)
Description: Cardiac magnetic resonance imaging (MRI) will be realized before Coronary Artery Bypass Grafting for assess atrial cardiomyopathy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample will be realized (4 tubes of 4ml blood, 16ml in total) before Coronary Artery Bypass Grafting.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac muscle biopsy
Description: Cardiac muscle biopsy will be realized during Coronary Artery Bypass Grafting.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter-electrocardiogram (ECG)
Description: Holter-electrocardiogram (ECG) will be realized 1 year after Coronary Artery Bypass Graftin during 3 days to diagnose the occurrence of atrial fibrillation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical examination
Description: medical examination will be realized 1 year after Coronary Artery Bypass Graftin. Theses datas will collected: events during the follow-up year and evaluation of the Holter-electrocardiogram result.
Study: NCT06249386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Description: BA reduces alcohol use and posttraumatic stress symptoms and increases psychosocial functioning via psychoeducation, activity monitoring, values clarification, and activity scheduling.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relapse Prevention (RP)
Description: RP reduces alcohol use via increasing awareness and avoidance of high-risk situations, enhancing drink refusal skills, improving assertiveness, and other strategies.
Study: NCT05934851

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Frozen-Section Directed Excision
Description: Frozen-Section Directed Excision (FSDE) is a surgical technique with evaluation of margin status during the surgical procedure, similar to the established Mohs Surgical Technique. The use of FSDE may ensure negative margins, decrease unnecessary excision of healthy tissue and has the potential to greatly reduce positive margins.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wide Local Excision
Description: Standard of care surgical technique utilized for VIN 2, VIN3, VIN 2/3 or High-grade Dysplasia NOS
Study: NCT06548100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mibavademab
Description: Administered by intravenous (IV) infusion followed by subcutaneous (SC) injection
Study: NCT05609409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FlexED
Description: Intervention consists of eight 20-30 minute sessions of a digital intervention based on Acceptance and Commitment Therapy (ACT). Participants learn skills of body image flexibility by following an avatar through a story line and completing interactive exercises.
Study: NCT06256510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Participants will receive a single dose of Midazolam by mouth in Period 1 Day 1, and Period 2 Day 1 and Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vepdegestrant
Description: Participants will receive Vepdegestrant by mouth once a day for 15 days in Period 2.
Study: NCT05583578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-based mobility testing and active tDCS
Description: A Soterix Clinical Trials tDCS unit will be used for delivery of stimulation for twenty minutes of 2.0mA direct current through two biocarbon rubber electrodes encased in saline soaked 5cm2 sponges placed over the frontal cortices at F3 and F4 (based on the international 10-20 system of standardized brain electrode placement). 2.0mA was

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham stimulation is performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2.0mA of direct current stimulation at the beginning of each rehabilitation session. Since participants habituate to the sensation of tDCS within 30-60 seconds of stimulation, this procedure provides the same sensation of active tDCS.
Study: NCT05877976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Arts Immersion
Description: Museum educators from The Metropolitan Museum of Art (MET) will provide a curriculum including an art immersion program that will select specific works/art in the museum as well as virtually that will help to stimulate self-reflection and prompt connection to their nursing practice. Participants will be asked to sign up for 2 art immersion classes. The first class will be an in-person class at The MET and the second class will be virtual via WebEx. Each class will last 60 minutes.
Study: NCT05053152

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Given PO

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SABR

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SABR
Study: NCT04482933

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological G207
Description: Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI
Study: NCT05660122

Intervention type: DRUG
Intervention: Fexuprazan Hydrochloride
Description: Fexuclue Tablet 40mg
Study: NCT06419959

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NightWare
Description: Nightware intervention app (enabled) will attempt to detect when an individual is having a nightmare based on a Nightware proprietary algorithm and attempt to disrupt the nightmare without awakening. In the sham comparator group the NightWare app will be disabled and not deliver an intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NightWare
Description: Nightware intervention app (enabled) will attempt to detect when an individual is having a nightmare based on a Nightware proprietary algorithm and attempt to disrupt the nightmare without awakening. In the sham comparator group the NightWare app will be disabled and not deliver an intervention.